Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

ived from

license agreements with Baxter Heathcare Corporation ($1.0 million)

and other license revenue, net of license fees due to licensors.

d. Change in estimate of accounting for excess and obsolete inventory

resulting from the alignment during the third and fourth quarters of

2007 of inventory policies across our various manufacturing

operations, and non-recurring supply / distribution agreement

termination costs.

e. Research and development adjustments:

---------------------------------------------------------------------

Year ended Year ended

Dec. 31, 2007 Dec. 31, 2006

------------------------------

Stock-based compensation (1,665) (2,490)

Non-recurring license fees due to

licensors (419) -

Termination and reorganization costs

related to the integration of AMI (849) -

Non-recurring supply / distribution

agreement termination costs (899) -

Non-recurring in-process research and

development expense relating to the

signing of a technology and intellectual

property license agreement (750) -

---------------------------------------------------------------------

(4,582) (2,490)

---------------------------------------------------------------------

f. Selling, general and administrative adjustments:

---------------------------------------------------------------------

Year ended Year ended


'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):ADA releases updated position paper on nutrient supplementation 2Why King Kong failed to impress 2Rodent smoke screen 2Death rates same for diabetes and heart disease patients receiving drug therapy or surgery 48111 1Death rates same for diabetes and heart disease patients receiving drug therapy or surgery 48111 2Recruitment of reproductive features into other cell types may underlie extended lifespan in animals 8735 1Recruitment of reproductive features into other cell types may underlie extended lifespan in animals 8735 2Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 1Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 2Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 3Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 4Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 5Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 6Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years 3A DURATION 1 Interim Long Term Data Present 4551 7